Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) is expected to be posting its Q2 2026 resultson Monday, August 17th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 20, 2026 at 8:30 AM ET.
Brainstorm Cell Therapeutics Stock Performance
BCLI stock opened at $0.79 on Monday. The company’s 50 day moving average is $0.93 and its 200 day moving average is $0.80. The stock has a market cap of $8.76 million, a price-to-earnings ratio of -0.23 and a beta of 0.23. Brainstorm Cell Therapeutics has a 1-year low of $0.46 and a 1-year high of $1.69.
Brainstorm Cell Therapeutics Company Profile
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
Read More
- Five stocks we like better than Brainstorm Cell Therapeutics
- Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
- Can DICK’S Turn Foot Locker Into a Winner?
- Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
